Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Wien Med Wochenschr ; 163(21-22): 495-8, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24221053

RESUMO

BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by lacking expression of estrogen receptor and progesterone receptor as well as absence of human epidermal growth factor receptor 2 overexpression and is an aggressive clinical phenotype. PATIENTS AND METHODS: We report the case of a 33-year-old woman who has been treated using a targeted approach for TNBC and developed a malignant melanoma metastasis without any primary. RESULTS AND CONCLUSION: Using targeted therapies, tumors can be treated much more effectively, but up to now, we do not know much about potential adverse reactions. Due to the targeted therapy, tumors may be pressurized for transformation. We call for further investigations to rule out the potential risks of targeted therapy in TNBC. This is the first report of a potential transforming of one tumor entity to another by a targeted therapy.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Ductal de Mama/tratamento farmacológico , Carcinoma Ductal de Mama/genética , Carcinoma Ductal de Mama/patologia , Transformação Celular Neoplásica/efeitos dos fármacos , Transformação Celular Neoplásica/genética , Melanoma/induzido quimicamente , Melanoma/patologia , Terapia de Alvo Molecular/efeitos adversos , Terapia de Alvo Molecular/métodos , Neoplasias Primárias Múltiplas/tratamento farmacológico , Neoplasias Primárias Múltiplas/genética , Neoplasias Primárias Múltiplas/patologia , Neoplasias Primárias Desconhecidas/induzido quimicamente , Neoplasias Primárias Desconhecidas/patologia , Neoplasias da Medula Espinal/induzido quimicamente , Neoplasias da Medula Espinal/patologia , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Neoplasias de Mama Triplo Negativas/genética , Adulto , Transformação Celular Neoplásica/patologia , Terapia Combinada , Ciclo-Oxigenase 2/genética , Progressão da Doença , Receptores ErbB/genética , Evolução Fatal , Feminino , Humanos , Antígeno Ki-67/genética , Melanoma/genética , Melanoma/secundário , Estadiamento de Neoplasias , Neoplasias Primárias Desconhecidas/genética , Receptor ErbB-2/genética , Neoplasias da Medula Espinal/genética , Neoplasias da Medula Espinal/secundário , Fator A de Crescimento do Endotélio Vascular/genética
2.
Curr Allergy Asthma Rep ; 12(2): 85-98, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22359067

RESUMO

The hypereosinophilic syndromes (HES) are a heterogeneous group of disorders defined as persistent and marked blood eosinophilia of unknown origin with systemic organ involvement. HES is a potentially severe multisystem disease associated with considerable morbidity. Skin involvement and cutaneous findings frequently can be seen in those patients. Skin symptoms consist of angioedema; unusual urticarial lesions; and eczematous, therapy-resistant, pruriginous papules and nodules. They may be the only obvious clinical symptoms. Cutaneous features can give an important hint to the diagnosis of this rare and often severe illness. Based on advances in molecular and genetic diagnostic techniques and on increasing experience with characteristic clinical features and prognostic markers, therapy has changed radically. Current therapies include corticosteroids, hydroxyurea, interferon-α, the tyrosine kinase inhibitor imatinib mesylate, and (in progress) the monoclonal anti-interleukin-5 antibodies. This article provides an overview of current concepts of disease classification, different skin findings, and therapy for HES.


Assuntos
Síndrome Hipereosinofílica/classificação , Síndrome Hipereosinofílica/diagnóstico , Dermatopatias/diagnóstico , Diagnóstico Diferencial , Humanos , Síndrome Hipereosinofílica/genética , Síndrome Hipereosinofílica/terapia , Dermatopatias/patologia , Dermatopatias/terapia
3.
Arch Dermatol ; 147(8): 963-6, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21482864

RESUMO

BACKGROUND: Octopus vulgaris is a common marine animal that can be found in nearly all tropical and semitropical waters around the world. It is a peaceful sea dweller with a parrotlike beak, and its primary defense is to hide through camouflaging adjustments. Bites from animals of the class Cephalopoda are very rare. We describe a boy who was bitten on his forearm by an Octopus vulgaris. OBSERVATION: A 9 -year-old boy was bitten by an Octopus vulgaris while snorkeling. There was no strong bleeding or systemic symptoms; however, 2 days later, a cherry-sized, black, ulcerous lesion developed, surrounded by a red circle that did not heal over months and therefore had to be excised. Histologic examination showed ulceration with extensive necrosis of the dermis and the epidermis. A microbial smear revealed Pseudomonas (formerly known as Flavimonas) oryzihabitans. After excision, the wound healed within 2 weeks, without any complications or signs of infection. CONCLUSIONS: To the best of our knowledge, this case represents the first report of an Octopus vulgaris bite resulting in an ulcerative lesion with slow wound healing owing to P oryzihabitans infection. We recommend greater vigilance regarding bacterial contamination when treating skin lesions caused by marine animals.


Assuntos
Mordeduras e Picadas/complicações , Mordeduras e Picadas/microbiologia , Octopodiformes , Infecções por Pseudomonas/etiologia , Úlcera Cutânea/etiologia , Úlcera Cutânea/microbiologia , Animais , Criança , Humanos , Masculino
4.
Expert Opin Emerg Drugs ; 15(2): 249-67, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20433363

RESUMO

IMPORTANCE OF THE FIELD: Atopic eczema (AE) is a chronic relapsing inflammatory skin condition and one of the most common, potentially debilitating diseases with increasing incidence. AREAS COVERED IN THIS REVIEW: The complex etiology of AE with multiple systemic and local immunologic and inflammatory responses and interactions between susceptibility genes and environmental factors leading to defects in skin barrier function and eczematous skin lesions is presented. Knowledge of pathogenesis is important for understanding the more innovative treatment approaches discussed. WHAT THE READER WILL GAIN: Basic therapy consists of hydrating topical treatment and avoidance of specific and unspecific provocation factors. For acute eczematous skin lesions, anti-inflammatory treatment consists mainly of topical glucocorticoids and topical calcineurin inhibitors (tacrolimus and pimecrolimus). Microbial colonization and superinfection may induce skin exacerbation, which can be treated by either topical or systemic antimicrobial treatment. Systemic anti-inflammatory therapy is limited to severe cases and consists of systemic steroids, cyclosporine A or mycophenolate mofetil. Novel anti-inflammatory concepts that go beyond corticosteroids are in the early phases of development. There are targeted therapeutic approaches, such as cytokine and chemokine modulators and it remains to be investigated how effective they will be and what side effects they may carry. TAKE HOME MESSAGE: Existing treatment modalities such as barrier repair therapy, topical immunosuppressive agents, antiseptic treatment as well as systemic treatment options are discussed. The review aims to summarize the most recent findings of more innovative treatment approaches such as modulation of cytokines or chemokines, modulation of T-cell responses or anti-IgE therapy.


Assuntos
Dermatite Atópica/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Drogas em Investigação/uso terapêutico , Administração Cutânea , Animais , Anti-Infecciosos Locais/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Produtos Biológicos/uso terapêutico , Dermatite Atópica/genética , Dermatite Atópica/imunologia , Fármacos Dermatológicos/administração & dosagem , Drogas em Investigação/administração & dosagem , Humanos , Imunossupressores/uso terapêutico , Imunoterapia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...